

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: RF2/22 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 30.09.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set 2</b>														
<b>(237) anti-streptolysin O (ASLO)</b>					20							18	18	100%
Samples and groups	[kU/L]													
<b>Sample A2</b>		113	13	11	20							18	18	100%
(58) Beckman Coulter (AU)		122	4,5	3,7	7	0	CVPG	123	2,4	20%	98,4	148	7	
(60) Roche		115	14	12	6	0	CVPG	120	3,4	20%	96	144	6	
Other					7	0							5	
								3x 1, 1x 5, 1x 149, 1x 162, 1x 178						
<b>Sample B2</b>		146	19	13	20							18	18	100%
(58) Beckman Coulter (AU)		156	5,5	3,5	7	0	CVPG	160	2,5	20%	128	192	7	
(60) Roche		148	19	13	6	0	CVPG	157	4,1	20%	125	189	6	
Other					7	0							5	
								3x 1, 1x 5, 1x 149, 1x 162, 1x 178						
st_kn_p														Printed: 07.10.2022
														End of report